At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 660 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Atopic Dermatitis. Completed, enrolled 660 participants across 93 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCzechia, Denmark, France, Germany, India, Italy, Japan, Mexico, Russia, Taiwan
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionDec 2018
Study CompletionAug 2019
TodayJul 2026
First PostedNov 7, 2017
Enrollment StartNov 23, 2017
Primary CompletionDec 6, 2018
Study CompletionAug 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.7 years ago
Interventions
Baricitinibdrug
Administered orally.
Placebodrug
Administered orally.